Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Return on Sales (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Return on Sales for 14 consecutive years, with 0.64% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 67.0% year-over-year to 0.64%, compared with a TTM value of 1.07% through Dec 2025, up 51.0%, and an annual FY2025 reading of 1.25%, up 46.0% over the prior year.
  • Return on Sales was 0.64% for Q4 2025 at Enanta Pharmaceuticals, up from 1.23% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.64% in Q4 2025 and bottomed at 3.47% in Q3 2021.
  • Average Return on Sales over 5 years is 1.54%, with a median of 1.33% recorded in 2023.
  • The sharpest move saw Return on Sales tumbled -232bps in 2021, then surged 218bps in 2022.
  • Year by year, Return on Sales stood at 1.09% in 2021, then dropped by -13bps to 1.23% in 2022, then tumbled by -51bps to 1.86% in 2023, then grew by 29bps to 1.31% in 2024, then soared by 51bps to 0.64% in 2025.
  • Business Quant data shows Return on Sales for ENTA at 0.64% in Q4 2025, 1.23% in Q3 2025, and 1.0% in Q2 2025.